Company Description
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space.
The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter.
The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system.
Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
| Country | United States |
| Founded | 2010 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Harel Gadot |
Contact Details
Address: 288 Grove Street, Suite 388 Braintree, Massachusetts 02184 United States | |
| Phone | 781 875 3605 |
| Website | microbotmedical.com |
Stock Details
| Ticker Symbol | MBOT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000883975 |
| CUSIP Number | 59503A204 |
| ISIN Number | US59503A2042 |
| Employer ID | 94-3078125 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Harel Gadot | Co-Founder, President, Chief Executive Officer and Chairman |
| Rachel Vaknin | Chief Financial Officer |
| Dr. Simon Sharon MBA, MSc | Chief Technology Officer and GM of Microbot Israel |
| Dr. Juan Diaz-Cartelle | Chief Medical Officer |
| Michal Ahuvia | Director of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 10, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 28, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 21, 2025 | 424B3 | Prospectus |
| Feb 18, 2025 | PRE 14A | Other preliminary proxy statements |
| Feb 18, 2025 | D | Notice of Exempt Offering of Securities |
| Feb 13, 2025 | EFFECT | Notice of Effectiveness |
| Feb 12, 2025 | 424B3 | Prospectus |